These benefits were sustained through 48 hours for some people. We are also working to bring NURTEC ODT to migraine suffers in international markets. In the United States, the prevalence rate is approximately 7%. Despite the approval of over two dozen agents, therapeutic effects are limited. The Company intends to advance BHV-1200 into a full clinical development program. Patents are a key determinant of market exclusivity for most pharmaceuticals. The patent applications have been filed in the U.S., Europe, Japan and other countries. Under the agreement, the Company may develop products based on the MoDE platform. Biohaven is obligated to pay FCCDC milestone payments for each NDA filing. A REMS can substantially increase the costs of obtaining approval. Section 505(b)(2) was enacted as part of the Hatch-Waxman Amendments. In August 2020, we drew down the first tranche of $275.0 million. There can be no assurance that any of these trials will produce positive results. In addition, there is a natural transition period when a new CRO commences work. If these collaborations are not successful, our business could be harmed. Any future collaborations that we enter into may not be successful. We have entered into several licenses to support our various programs. In March 2020, the World Health Organization declared COVID-19 a pandemic. The spread of COVID-19 may reduce access to NURTEC ODT.